Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.
Epistemonikos ID: 621363f2fef06b333d155b7a63a3b71b0b7dd52b
First added on: Dec 19, 2025